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ObjectiveaaThis study was conducted to confirm the results of the authors’ previous research on schizophrenia manifesting high serum 
homocysteine and low folate levels. This study is anchored on a theory that a high serum homocysteine concentration affects schizo-
phrenia by virtue of a neurotoxic mechanism, and on a report that some schizophrenia patients with high homocysteine levels benefited 
from high folate ingestion.
MethodsaaThe serum homocysteine, folate, and vitamin B12 levels of 236 normal-control-group subjects and 234 schizophrenia sub-
jects who met the diagnostic criteria based on DSM-IV-TR were compared. The homocysteine levels were measured via fluorescence 
polarization immunoassay, and the folate and vitamin B12 levels were determined via radioimmunoassay. 
ResultsaaThe homocysteine levels of the patient group were significantly higher than those of the normal control group. The homocys-
teine level was more negatively correlated with the folate level in the schizophrenia group than in the control group. The percentages of 
female and male schizophrenia subjects manifesting high homocysteine levels were 33.8 and 51.5%, respectively. The percentage of schizo-
phrenia subjects with low folate levels was 66.2%. In the low- and normal-folate-level groups, the patient group showed significantly high-
er homocysteine levels than the normal control group. The low-folate-level patient group particularly showed significantly higher homo-
cysteine levels than the low-folate-level normal control group.
ConclusionaaSome schizophrenia patients with high serum homocysteine levels may have the genetic defect of having low folate serum levels. 
In such cases, folate ingestion may be a good management modality for clinical improvement.  Psychiatry Investig 2011;8:134-140
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INTRODUCTION
Extensive studies have revealed that increased serum ho-
mocysteine is a risk factor of cardiovascular diseases such as 
myocardial infarction, carotid stenosis, cerebral hemorrhage, 
and vascular dementia; of neuropsychiatric diseases, includ-
ing the neural-tube defect; of degenerative diseases such as 
Alzheimer’s disease, mild cognitive impairment, and Parkin-
son’s disease; and of depressive disorder and schizophrenia.
1-7 
For the pathological mechanism of the cardiovascular system, 
homocysteine is known to hamper vasodilation by hindering 
deoxyribonucleic acid (DNA) synthesis in the vascular endo-
thelial cell. It is also known to disturb anticoagulation,
8 but 
its pathological mechanism for the central nervous system re-
mains unclear. For the brain nerve cells, it has been asserted 
that DNA damage inflicted by homocysteine induces apop-
tosis and hypersensitivity to excitotoxicity.
9 Other studies as-
serted that homocysteine acts as an excitotoxin on a glycine 
coagonist site and on a glutamate site in the N-methyl-D-as-
partate (NMDA) receptors.
10
With the growing interest in increased homocysteine, it was 
found that the major cause of the aforementioned diseases is 
a defect in the 5,10-methyleneterahydrofolate reductase (MT-
HFR), which remethylates homocysteine into methionine. 
Many studies reported that the administration of folate can 
treat the genetic defect of MTHFR.
11-13
Regland et al.
13 showed that in a 27-year-old female patient 
with schizophrenia but who showed an improvement in her 
symptoms after taking the MTHFR catalyzer cobalamine, the 
cause of her metabolic disorder of increased homocysteine 
was that her low 5-methyl-terahydrofolate activity led to a re-
duction in methyleneterahydrofolate, which in turn led to the TH Kim & SW Moon
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non-remethylation of methyleneterahydrofolate into methio-
nine. Therefore, it is considered that the genetic defect of MT-
HFR is the primary cause of increased serum homocysteine.
14-16 
The secondary causes are low serum folate and cobalamine 
levels, which further increase homocysteine.
In Korea, there has yet to be a study on homocysteine and 
on the genetic variation of MTHFR in schizophrenia patients. 
In this context, this study was conducted for the following 
reasons on schizophrenia patients and on normal people who 
visited the authors’ hospital for physical examination: 1) to 
determine if there is a difference between the serum homocy-
steine, folate, and vitamin B12 levels of the schizophrenia pa-
tients and those of the normal control group; 2) to identify 
which variables affect the level of homocysteine in both the 
schizophrenia patients and the normal control group; and 3) 
to determine if there is any difference in the clinical variables 
between the patients with increased serum homocysteine 
and those with low serum homocysteine levels. If meaning-
ful data can be obtained from this study, folate can be admin-
istered to schizophrenia patients with abnormal homocyste-
ine metabolism, as a recommended treatment.
METHODS
Study subjects
Patient group
Patients who met the diagnostic criteria of schizophrenia 
based on DSM-IV-TR
17 and who did not have a history of any 
other physical, mental, or genetic disease were included in 
this study. All the schizophrenia patients were in a non-acute 
phase of the illness. They were treated with antipsychotic 
drugs, but none of them took any vitamin supplement three 
months before their inclusion in this study. There were 234 
subject patients in all, each of whom submitted a written in-
formed consent after being fully informed of the purpose and 
procedure of this study.
Normal control
Among the people who underwent physical examination 
for employment, 234 who had no history of physical, mental, 
or genetic disease were included in the study. They also did 
not take any vitamin supplement three months before their 
inclusion in this study. Given that among many circumstan-
tial factors, excluding age and sex, smoking and coffee drink-
ing have been known to increase serum homocysteine the 
most,
18 the normal subjects were matched based on their sex, 
age, smoking status, and coffee intake, using 1 : 1 matching. 
For smoking and coffee drinking, five cigarettes or more and 
three cups of coffee or more per day were chosen as the criteria.
Methods
Measurement of serum homocysteine, folate, and  
vitamin B12
10 mL blood samples were taken from the subjects’ antecu-
bital veins before breakfast and were placed in ice-cooled eth-
ylenediaminetetraacetic acid tubes. The samples were kept 
on ice for 2 hours, and the plasma and blood cells were sepa-
rated via centrifugation. The plasma samples were stored at 
-70°C until the homocysteine levels were measured via po-
larization immunoassay.
The amount of homocysteine was determined via radioim-
munoassay (IMx, Abbott, USA) while the amounts of folate 
and vitamin B12 were determined via radioimmunoassay 
(Cobra II, Packard, USA).
Classification of the clinical variables 
of the schizophrenia patients
Two psychiatrists assessed and classified the clinical courses, 
prognoses, and subtypes of schizophrenia of all the subject pa-
tients based on their age of onset, family history of schizoph-
renia, positive/negative symptoms, presence of auditory hal-
lucination, recovery period, and number of days of hospita-
lization, after reviewing the medical chart and interviewing 
the patients.
Statistical analysis
The demographic differences between the patient and con-
trol groups were analyzed using chi-square tests. The plasma 
concentrations of homocysteine, folate, and vitamin B12 of the 
patient and control groups, and the differences in homocyste-
ine concentration between the low- and high-folate-level gr-
oups, were measured via t-tests. The age of onset of schizoph-
renia of the high- and low-homocysteine-level groups were 
compared also via t-tests while the other items were assessed 
via chi-square tests. The correlation between the variables was 
studied using Pearson’s correlation analysis. Logistic regres-
sion analysis was conducted to estimate the schizophrenia 
risk factor. Statistical analysis was carried out using Statistical 
Package for the Social Sciences (SPSS) for the Windows 12.0 
software (SPSS Inc., Chicago, IL, USA).
RESULTS
Characteristics of the patient and normal control 
groups
The average ages of the patient group (n=234) and normal con-
trol group (n=234) were 40.4±10.5 (mean±SD) and 39.6± 
13.6 (mean±SD), respectively. The numbers of males (n=99) 
and females (n=135) were the same in each group. There was 136  Psychiatry Investig 2011;8:134-140
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no significant difference between the patient and normal con-
trol groups in terms of the age and number of males and females 
therein.
Comparison of the homocysteine, folate, and 
vitamin B12 levels of the patient and normal 
control groups
The homocysteine levels were significantly higher in the pa-
tient group than in the normal control group. In contrast, the 
folate levels were significantly lower in the patient group than 
in the normal control group. The vitamin B12 levels were with-
in the normal range in both groups, although they were signi-
ficantly higher in the patient group than in the normal con-
trol group. The reason for the higher vitamin B12 levels in the 
patient group is that the compound vitamin B was adminis-
tered to the patients in the two hospitals where such patients 
were hospitalized (Table 1).
Correlation between homocysteine and folate in the
patient and normal control groups
The coefficient of the inverse correlation between homo-
cysteine and folate was higher in the patient group (-0.313, p< 
0.01) than in the normal control group (-0.276, p<0.01). There 
was also an inverse correlation between homocysteine and 
vitamin B12 in both groups, although the coefficient of the in-
verse correlation was slightly different between the groups 
(Table 2).
Comparison of the homocysteine levels 
of the low-folate-level patient group and 
of the normal control group
In this study, a low serum folate level was defined as 3.8 
ng/mL or less, according to the criteria presented by Suzzer et 
al. (The serum folate level was 3.8 ng/mL or less in the lower 
one-third of the normal control group).
19 In the comparison 
of the serum folate levels of the patient group with low serum 
folate levels and of the normal control group, the number of 
subjects with low serum folate levels was remarkably high 
(115) compared with the normal control group (80), while 
the patient group showed significantly higher homocysteine 
levels than the normal control group. In the comparison of the 
patient group with normal serum folate levels and the normal 
control group, the serum homocysteine levels were signifi-
cantly higher in the patient group than in the normal control 
group (Table 3).
Correlation between the homocysteine levels and the 
clinical features of the schizophrenia patients
In this study, increased serum homocysteine was defined 
as 12.46 μM/L according to the criteria presented by Virgos 
et al. (the serum homocysteine level was 12.46 μM/L in 90% 
of the normal control group).
20 When the patient group was 
divided into the patient group with high serum homocyste-
ine levels and the patient group with normal serum homo-
cysteine levels using this criterion, 33.8% of all the patients 
belonged to the patient group with high serum homocyste-
ine levels. In particular, 51.5% of the male patients belonged 
to the patient group with high serum homocysteine levels. 
For the clinical variables, only sex registered a significant dif-
ference between the two groups. In the patient group with 
normal serum homocysteine levels, there were more women 
than men, and conversely, in the patient group with high se-
rum homocysteine levels, there were more men than women 
(Table 4 and 5).
Regression analysis of the risk factor of schizophrenia
The serum homocysteine, folate, and vitamin B12 levels as 
Table 1. Plasma concentrations of homocysteine, folate, and vita-
min B12
Variables
Schizophrenia Control 
p (N=234) (N=234)
(Mean±SD) (Mean±SD)
Homocysteine (μM/L)* 14.30±13.10 9.12±6.36 <0.001 
Folate (ng/mL)* 3.78±2.27 5.70±3.53 <0.001 
Vitamin B12 (pg/mL)* 690.34±314.41  601.78±211.20 <0.001 
*p<0.05 by independent t-test
Table 2. Correlations among homocysteine, folate, and vitamin B12
Homocysteine-
folate
Homocysteine-
vitamin B12
Schizophrenia group (N=234) -0.313* -0.285*
Control group (N=236) -0.276* -0.283*
*p<0.01 by Pearson’s correlation
Table 3. Difference in homocysteine concentration between the low- and normal-folate-level groups
Variables
Homocysteine  concentration (uM/L)
Low-folate-level group* Normal-folate-level group
Schizophrenia (N=234) 16.88±15.11† (N=155) 9.23±4.72‡ (N=79)0
Control (N=234) 12.44±9.88† (N=80) 7.58±2.12‡ (N=154)
*low folate level: ≤3.8 ng/mL, the bottom tertile for the control, †schizophrenia vs. control: p=0.004 via independent t-test, ‡schizophrenia vs. con-
trol: p=0.004 via independent t-testTH Kim & SW Moon
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predictor variables differed significantly between the patient 
group and the normal control group. In the patient group with 
increased serum homocysteine, the probability of the inci-
dence of schizophrenia was 1.609 times higher than that in 
the patient group with normal serum homocysteine levels. 
Meanwhile, increased serum folate was found to reduce the 
probability of the incidence of schizophrenia. These vari-
ables, however, were not suitable for use as decisive predictor 
variables because their odd ratios were not sufficiently large.
DISCUSSION
Homocysteine, a sulfur amino acid, is an intermediate me-
tabolite that is formed in the course of its conversion from 
methionine into cysteine. Homocysteine is metabolized via 
either of two major pathways. In remethylation, homocyste-
ine is converted into methionine by methionine synthase, wh-
ich uses vitamin B12 as a cofactor. For this conversion, the me-
thyl group is provided by MTHF, which is produced by a re-
action catalyzed by MTHFR. Second, it can be metabolized 
into cysteine via transsulfation. Homocysteine is metabolized 
into cysteine by cystathionine β-synthase, a vitamin-B6-de-
pendent enzyme. In the brain, remethylation is the one and 
only metabolic pathway.
The metabolism of homocysteine is most highly affected 
by the folate level and also by various environmental factors, 
such as food, in addition to genetic factors, typically MTHFR. 
An increase in serum homocysteine is brought about by smok-
Table 4. Demographic difference between the high- and normal-
homocysteine-level schizophrenia groups   
Variables
Normal-  
homocysteine-
level group (below 
12.46 μM/L) 
(N=155)
High- 
homocysteine-
level group (above 
12.46 μM/L) 
(N=79)
p
Sex* <0.001 
    Male (N=99) 048 51
    Female (N=135) 107 28
Age (years)*
    Below 29 (N=31) 021 10 0.808
    30-39 (N=68) 042 26
    40-49 (N=86) 060 26
    50-59 (N=40) 027 13
    Above 60 (N=6) 005 04
Family Hx* 0.588
    Absence (N=191) 125 66
    Presence (N=43) 030 13
Age at onset† 28±10.0 27.1±10.8 0.524
*chi square, †t-test were done
Table 5. Clinical difference between the high- and normal-homocysteine-level schizophrenia groups
Variables
Normal-homocysteine-level group
(below 12.46 μM/L) (N=155)
High-homocysteine-level group
(above 12.46 μM/L) (N=79)
p*
Positive/negative sx. 0.192
    Negative (N=56) 036 20
    Positive (N=170) 116 54
    Positive/Negative (N=6) 002 04
Course 0.165
    Acute recovered (N=54) 040 14
    Chronic deteriorate (N=180) 115 65
Prognosis 0.093
    Good (N=11) 008 03
    Moderate (N=113) 082 31
    Bad (N=1,110) 065 45
Disease subtypes 0.266
    Undifferentiated (N=77) 083 37
    Paranoid (N=110) 022 11
    Disorganized (N=33) 046 31
    Residual (N=4) 004 00
Auditory hallucination 0.563
    Absence (N=30) 018 12
    Presence (N=203) 137 66
High homocysteinemia: ≥12.46  μM/L, the 90th percentile for the control group. *p values calculated via chi-square test138  Psychiatry Investig 2011;8:134-140
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ing, coffee, age, vitamin B6, vitamin B2, the male gender, alco-
hol consumption, creatinine, and hypertension.
14,18 The nor-
mal serum homocysteine level is 5-15 μM/L, and its level in ce-
rebrospinal fluid and in the brain tissue is known to be 0.5-10 
μM/L.
19 At present, the mechanism of neurodegeneration 
due to increased serum homocysteine remains unclear.
Kruman et al.
9 observed that homocysteine induced the 
susceptibility of the hippocampal-nerve cells in a rat to apop-
tosis and excitotoxicity by damaging the DNA of the hippo-
campal-nerve cells. In addition, Lipton et al.
21 reported that 
under certain morbid conditions, such as shock or head in-
jury, the neurotoxic effect of homocysteine overwhelms its 
normal neuroprotective effect because homocysteine acts as 
a partial antagonist for the glycine coagonist site of the NM-
DA receptor. Spiro et al.
22 in their study on schizophrenia pa-
tients who had homocystinuria, suggested the possibility of 
the abnormality of methionine metabolism in some of the 
patients. They further reported that when methionine, a pre-
cursor of homocysteine, was administered to the schizophre-
nia patients, their symptoms were aggravated.
22,23 The admi-
nistration of betaine (a methyl donor) to the patients also ag-
gravated their symptoms.
24
Since the late 1990s, systematic studies have been perform-
ed on patients with schizophrenia due to homocysteine, and 
on normal control subjects. In a study conducted on schizo-
phrenia patients, Regland et al.
25 reported that a high homo-
cysteine level was observed in 45% (nine of the 20 patients) 
of the patient group, asserting that the high homocysteine 
level was due to a genetic defect associated with methylation 
regardless of the patient’s nutritive conditions, such as the lev-
el of folate or cobalamine, or psychotropic-drug administra-
tion. Unlike in the previous studies, however, Virgos et al.
20 re-
ported that in a comparative study of 210 Spanish schizoph-
renia patients and 218 Spanish normal control subjects, only 
10% of the schizophrenia patients showed high serum ho-
mocysteine levels because of their folate-rich Mediterranean 
diet. There was no difference between the serum homocyste-
ine levels of the two groups. This study by Virgos et al.
20 came 
under fire, however, because most of the study subjects were 
male whose average age was 58. Levine et al.
7 compared 193 
schizophrenia patients and 762 normal control subjects based 
on sex and age. Consistent with the clinical trend in which the 
onset of schizophrenia occurs at a rather early age for men, 
and in which the degenerative course is common, the result 
of the comparison showed that the serum homocysteine lev-
el was significantly higher in the young patient group. Levine 
et al.
7 postulated that the higher serum homocysteine levels 
in the young patient group were due to their high stress lev-
els, which enabled toxic substances to easily pass through their 
serum brain barriers (BBBs).
In this study, the serum homocysteine level was signifi-
cantly higher in the patient group than in the normal control gr-
oup, regardless of age. A high serum homocysteine level corres-
ponding to 90 percentile of the normal control group was ob-
served in 33.7% of the schizophrenia patients, particularly in 
51.5% of the male patients, similar to 45% in the study by Re-
gland et al.
25 Although consistent with the result of the study 
by Levine et al.
7 the serum homocysteine level was also high 
in the males in this study, and no clinical characteristics (e.g., 
early onset and degenerative course of the schizophrenia) 
were observed. There have been many reports that the admi-
nistration of folate to schizophrenia patients with MTHFR 
defects normalized their serum homocysteine levels.
12,13,26 
Mudd et al.
27 reported that one of three schizophrenia patients 
who had an MTHFR defect showed improvement in his symp-
toms after taking folic acid. Freeman et al.
12 also reported that 
the administration of folate to a mildly mentally retarded fe-
male teenager who had a high homocysteine level due to a 
disorder in her MTHFR activity improved her symptoms. Sus-
ser et al.
28 asserted that there are patients with schizophrenia 
who have a folate-sensitive homocysteine metabolism disor-
der, reporting that the serum homocysteine level was signifi-
cantly higher in the patient group with low serum folate levels 
than in the normal control group with low serum folate levels. 
There was no difference, however, between the homocysteine 
levels of the patient group with normal serum folate levels and 
those of the normal control group.
In this study, most of the schizophrenia patients belonged to 
a group with low serum folate levels, whereas the normal con-
trol group belonged to a group with high or normal serum fo-
late levels. For both groups with either low or high serum folate 
levels, the patient group showed higher serum homocysteine 
levels than the normal control group. Moreover, the coefficient 
of the inverse correlation between homocysteine and folate 
was higher in the patient group than in the normal control gr-
oup. In particular, the schizophrenia patients who had low 
serum folate levels showed exceptionally high serum homo-
cysteine levels compared with the normal control group.
The results of this study are similar to those of most of the 
previous studies, although Petronijević et al.
1 reported that 
no significant correlation between the plasma homocysteine 
and folate levels in the patients was shown upon their admis-
sion into the hospital. In particular, consistent with the result 
of the study conducted by Susser et al.
29 the homocysteine lev-
els were higher in the patient group with low serum folate le-
vels than in the normal control group with low serum folate 
levels. The result of this study, however, differed from that of 
Virgos et al.
20 who reported that only 10% of the schizophre-
nia patients in their study showed high serum homocysteine 
levels, and that there was no difference between the serum ho-TH Kim & SW Moon
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mocysteine levels of the patient and normal control groups. 
This difference is attributed to the folate-rich Mediterranean 
diet of the subjects in the study conducted by Virgos et al.
20 
Thus, considering the possibility that the subjects in this st-
udy had a low-folate diet because they were hospitalized in a 
mental hospital, where a folate-rich diet was unavailable, it was 
postulated that there could be many schizophrenia patients who 
have a folate-sensitive homocysteine metabolism disorder.
In this study, as the odd ratios of the risk of high serum ho-
mocysteine and vitamin B12 levels for schizophrenia were me-
rely 1.07 and 1.003, respectively, they cannot be used as deci-
sive predictors of the onset of the disease. In contrast, for a 
high serum folate level, the odd ratio was 0.84, indicating 
that it reduced the possibility of the incidence of schizophre-
nia, consistent with the result of Regland et al.
28 who asserted 
that folate could help prevent the incidence of schizophrenia.
Taken together, for people who have a genetic homocyste-
ine metabolism disorder and who have a low folate intake, a 
high serum homocysteine level is expected to occur, which 
may be consequently affected by the onset, symptoms, and 
course of schizophrenia. The major limitation of this study is 
that it did not make use of a more objective measurement 
tool to identify the clinical features of the schizophrenia pa-
tients. Subsequently, the clinical data had low reliability. In 
addition, due to the fact that the subject schizophrenia patients 
were in-patients in a mental hospital, they had a low-folate 
diet compared with the normal control subjects. Further stud-
ies are required to identify the clinical features of schizophre-
nia patients who have high and normal serum homocysteine 
levels, using more objective study tools, such as PANSS (posi-
tive-and-negative-syndrome scale), which was used in the 
study of Petronijević et al.
1 
Moreover, to determine the changes in the homocysteine 
level and psychopathology, follow-up studies must be con-
ducted on schizophrenia patients who have high serum homo-
cysteine levels due to a genetic MTHFR defect, and on those 
who have low serum folate levels, after the administration of 
a sufficient amount of folate.
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